We retrospectively analysed the significance of FLT3 mutations in patients with acute myeloid leukemia (AML) having a normal karyotype, who were treated with highdose chemotherapy and autologous peripheral blood stem cell transplantation (auto-PBSCT). In all, 34 patients with normal karyotype AML in first complete remission receiving high-dose chemotherapy and auto-PBSCT were analysed based on the presence or absence of FLT3/ITDs and FLT3/D835. They were 16 males and 18 females and with a median age of 41.5 years. FLT3/ITDs were detected in eight of 34 patients (23.5 %), and FLT3 D835 mutations in two of 34 patients (5.9%). White blood cell count (P ¼ 0.0087), serum concentration of lactate dehydrogenase (P ¼ 0.005), and percentages of peripheral blood (P ¼ 0.0131) and bone marrow (BM) blasts (P ¼ 0.0312) were significantly higher in patients showing the FLT3 mutations. Overall survival (OS) and diseasefree survival (DFS) were similar between patients with or without FLT3 mutations (5 year DFS, 67.5 vs 68.55%, P ¼ 0.819; 5 year OS, 64.81 vs 78.88%, P ¼ 0.4457, by the log-rank test). FLT3 mutations demonstrate no further prognostic impact in patients with normal karyotype AML in first CR treated with high-dose chemotherapy and auto-PBSCT. Myeloablative chemotherapy supported by auto-PBSCT may overcome any poor prognostic implications of FLT3 mutations. Bone Marrow Transplantation (2005) 36, 977-983.
peripheral blood stem cell transplantation By conventional chromosome-banding analysis, approximately 35-50% of acute myeloid leukemia (AML) patients lack clonal chromosomal aberrations, 1 and a normal karyotype has been reported to indicate intermediate risk AML. [2] [3] [4] The role of high-dose chemotherapy supported by autologous peripheral blood stem cell transplantation (auto-PBSCT) remains to be determined as a postremission therapy for AML in first complete remission (CR). We have previously reported encouraging results of auto-PBSCT as a postremission therapy for AML in first CR. 5, 6 FMS-like tyrosine kinase 3 (FLT3), a member of the class 3 receptor tyrosine kinase (RTK) family, is preferentially expressed on hematopoietic progenitor cells 7 and mediates proliferation and differentiation of early hematopoietic progenitors in cooperation with other hematopoietic growth factors and interleukins (IL). 8 Two types of activating FLT3 mutations have been described in AML. An internal tandem duplication (ITD) of the FLT3 gene (FLT3/ITDs) can be detected in 20-30% of younger adult patients with AML. [9] [10] [11] [12] [13] [14] [15] This duplication involves a segment of the juxtamembranous (JM) domain-coding sequence (exon 14 and 15) in direct head-to-tail orientation and is always in-frame. 9, 10, 16 In vitro, FLT3/ITDs cause ligandindependent receptor dimerization and constitutive activation of the TK domains. 17 Point mutations of Asp835 (FLT3/D835 mutations) within the FLT3 TK domain have recently been shown in 7% of adult AML patients. 18 Like FLT3/ITDs, FLT3/D835 mutations cause constitutive activation of the receptor. Activating FLT3 mutations have been reported to be a negative prognostic factor in intermediate risk AML. [12] [13] [14] In this paper, we retrospectively analysed the prognostic significance of FLT3 mutations in patients with normal karyotype AML who survived induction and consolidation and were capable of pursuing auto-PBSCT.
Materials and methods

Patient samples
We analyzed 34 patients with normal karyotype AML in first CR who were treated with high-dose chemotherapy and auto-PBSCT between April 1995 and December 2003. There were 16 male patients and 18 female patients with a median age of 41.5 years range 15-74 years. Cytogenetic G-banding analysis was performed with a standard method. The definition of a cytogenetic clone and descriptions of karyotypes followed the International System for Human Cytogenetic Nomenclature. A minimum of 20 bone marrow (BM) metaphases/case were required to be examined for a case to be classified as having normal karyotype. Morphologic types of AML according to the FAB classification 19, 20 were as follows; M0 was in one patient, M1 in 12 patients, M2 in eight patients, M4 in seven patients, and M5 in six patients. Details of patients including a white blood cell count (WBC), a hemoglobin concentration (Hb), a platelet count (Plt), a serum concentration of lactate dehydrogenase (LDH), and percentages of peripheral blood (PB) and BM blasts at the time of initial diagnosis and median interval days from diagnosis to auto-PBSCT, a number of infused CD34 þ cells, median days to granulocytes exceeding 500/mm 3 , and to platelets exceeding 50 000/mm 3 after auto-PBSCT are shown in Table 1 . All of the patients or guardians gave their written informed consents in accordance with the requirements of the Institutional Review Board.
Treatment protocols
Induction chemotherapy consisted of idarubicin (IDR) 12 mg/m 2 or daunorubicin (DNR) 45 mg/m 2 intravenously for 3 days and cytosine arabinoside (Ara-C) 100 mg/m 2 by continuous infusion for 7 days.
Consolidation chemotherapy of Ara-C 500 mg/m 2 intravenously every 12 h for 6 days combined with mitoxantrone 7 mg/m 2 intravenously for 3 days in the first course and etoposide 100 mg/m 2 intravenously for 5 days in the second course, was started after achieving CR. Collection of peripheral blood stem cells (PBSC) was performed with a continuous blood-cell separator during hematopoietic recovery after each cycle of consolidation chemotherapy with or without granulocyte-colony stimulating factor (G-CSF) (Filgrastim, 200 mg/m 2 intravenously). 5, 6 Unpurged PBSC harvests were cryopreserved by a simplified method without rate-controlled freezing until transplantation as previously described. 21 The pretransplant conditioning regimen was G-CSF combined with the BEA regimen, which included G-CSF at a dose of 200 mg/m 2 on days À12 to À6, 400 mg/m 2 on days À5 and À4 by intravenous infusion in combination with continuous infusion of Ara-C 100 mg/m 2 on days À10 to À4, in addition to busulfan 4 mg/kg orally on days À9 to À6, etoposide 20 mg/kg intravenously on days À5 and À4, and Ara-C 3 g/m 2 intravenously every 12 h on days À3 and À2. 5, 6 One day later, cryopreserved PBSC were thawed rapidly in a 371C water bath and infused through a central venous catheter without washing on day 0. G-CSF (200 mg/m 2 ) was administered intravenously from day 1 until the day of sustained neutrophil engraftment.
Analysis of FLT3/ITDs and FLT3/D835 mutations
Genomic DNA was isolated from BM slides at the time of initial diagnosis. Cells were stripped from the slides and dissolved in phosphate-buffered saline (PBS). Genomic DNA was extracted using QIAamp DNA mini kits (QIAGEN, Hilden, Germany) according to the manufacturer's recommendations.
For FLT3/ITDs, polymerase chain reaction (PCR) amplification of genomic DNA was carried out as previously described, 11 using primers 11F and 12R located on FLT3 exon 14 and 15. PCR products were separated by electrophoresis using 3% Nusieve GTG agarose gel (Cambrex Bio Science Rockland, Rockland, ME, USA). FLT3/ITDs were detected as abnormal larger products, which were cut out from the gel, purified with a QIAquick Gel Extraction kit (QIAGEN) and cloned into the PCR II-TOPO vector (Invitrogen, San Diego, CA, USA) according to the manufacturer's recommendations. Sequencing was performed using the ABI PRISM BigDye Terminator V 1.1 Cycle Sequencing Kit and 21M13 and T7 primer on an ABI 310 Prism sequencer (Applied Biosystems, Foster City, CA, USA).
For FLT3/D835 mutations, exon 20 of the FLT3 gene was amplified by genomic DNA PCR as previously described 18 and directly sequenced to investigate the presence of FLT3/D835 mutations.
Statistical analysis
In order to evaluate differences between patients with or without FLT3 mutations, pairwise comparisons of binary variables such as gender, FAB classification, and a kind of induction therapy were conducted using the Fisher's exact test. Pairwise comparisons of continuous variables such as age, WBC, Hb, Plt, LDH concentration, percentages of PB and BM blasts, median interval days from diagnosis to auto-PBSCT, number of infused CD34 þ cells, median days to granulocytes exceeding 500/mm 3 , and to platelets exceeding 50 000/mm 3 after auto-PBSCT were conducted using the Mann-Whitney U-test. For the clinical variables reporting a significant P-value at the 0.05 level, pairwise comparisons were conducted.
DFS was calculated as the time from CR to relapse or death. OS was calculated as the time from diagnosis to death. DFS and OS were calculated according to the Kaplan-Meier method, and comparisons between FLT3 mutations positive and negative patients were made with the log-rank test and the Cox proportional hazards model.
Results
Incidence of FLT3/ITDs and FLT3/D835 mutations in normal karyotype AML FLT3/ITDs were detected in eight of 34 patients (23.5%). Although FLT3/ITDs varied in both position and length from 21 to 102 bp, these were always in-frame and limited to the JM domain. Loss of the normal FLT3 allele was not detected in any patients. FLT3 D835 mutations were detected in two of 34 patients (5.9%). By direct sequencing analysis of PCR products, the first nucleotide G of D835 was substituted with T in both patients, resulting in an (Figure 1) .
Discussion
In the present study, we analysed activating FLT3 mutations in normal karyotype AML patients in first CR treated with auto-PBSCT. Since this is a retrospective analysis, there are several intrinsic limitations such as patient selection. 22 To precede auto-PBSCT, patients must obtain CR and maintain remission during consolidation therapy with sufficient PBSC mobilization. Thus, patients who did not achieve CR or who relapsed early during consolidation therapy were excluded from our analysis. As shown in Table 2 , the presence of FLT3/ITDs in adult patients does not seem to affect the probability of achieving CR. The most significant impact of FLT3/ITDs is its association with an increased risk of relapse and decreased DFS and OS, which have been reported in most studies of adult patients with AML younger than 60 years of age. 10, [12] [13] [14] 16, 23 The incidence of FLT3/ITDs observed in our study (23.5%) is similar to previous reports of the intermediate cytogenetic risk groups, and does not support any marked bias of patient selection in this study.
FLT3 mutations are regarded as one of the most significant prognostic factors in normal karyotype AML. [11] [12] [13] [14] [15] [24] [25] [26] Several previous studies have suggested that the presence of FLT3/ITDs is associated with poor prognosis in younger adult patients with AML. However, these data were obtained in patient populations that were highly heterogeneous with regard to patients' age, karyotype, and treatment regimens. Focusing on intermediate cytogenetic AML as shown in Table 2 , many studies have reported that FLT3 activating mutations are a significant negative prognostic factor, while Boissel et al 23 and Schnittger et al 24 have shown that activating FLT3 mutations in intermediate cytogenetic AML have no significant clinical impact. As a postremission therapy, intermediate-dose Ara-C was employed in Boissel's study and high-dose Ara-C was used in Schnittger's study. These results suggest that intensification of chemotherapy might overcome any negative impact of FLT3 mutations. In contrast, in the study by Frohling et al, 14 a negative prognostic effect was shown of activating FLT3 mutations despite a treatment regimens including double-induction therapy, followed by intensive consolidation with high-dose Ara-C. Intensive consolidation chemotherapy using highdose Ara-C has been shown to improve DFS and OS of younger adult patients with normal karyotype AML. 2, 27 However, it remains to be determined whether or not intensification of chemotherapy could overcome the negative impact of FLT3 mutations. The most powerful intensification of chemotherapy is myeloablative chemotherapy facilitated by autologous stem cell rescue. Previously, Whitman et al 13 indicated that DFS and OS for without FLT3/ITDs and with FLT3/ITDs and normal FLT3 groups did not differ in the study employing auto-PBSCT using high-dose etoposide and Ara-C for 'in vivo purging' and stem cell mobilization followed by a myeloablative regimen of busulfan and etoposide. However, since eight of 82 patients could not receive auto-PBSCT and their treatment regimens included induction therapy with PSC-833 as a MDR modulator and post transplant IL-2 therapy, the role of auto-PBSCT in their study was difficult to evaluate.
As far as we know, this is the first report to describe the significance of FLT3 mutations in patients with normal karyotype AML in first CR receiving myeloablative chemotherapy with auto-PBSCT. We cannot demonstrate that FLT3 mutations have negative prognostic implication in patients with normal karyotype AML when they were treated with auto-PBSCT. Our data suggest that myeloablative chemotherapy may overcome the negative impact of FLT3 mutations. However, our analysis was retrospective with a limited numbers of patients, and we should be cautious at interpreting the result. To obtain definitive findings, a prospective study with a larger numbers of patients is necessary. We are investigating the impact of FLT3/ITDs prospectively in newly diagnosed AML patients presently.
In conclusion, in this retrospective analysis, we show that FLT3 mutations have no further prognostic implications in patients with normal karyotype AML who gain first CR and proceed to myeloablative chemotherapy with auto-PBSCT. The prognostic significance of activating FLT3 mutations in patients with normal karyotype AML should be evaluated in relation with post-remission therapeutic modalities.
